<DOC>
	<DOCNO>NCT02224755</DOCNO>
	<brief_summary>The objective study evaluate safety effectiveness HM3 LVAS demonstrate non-inferiority HMII LVAS ( HMII ) use treatment advance , refractory , leave ventricular heart failure .</brief_summary>
	<brief_title>MOMENTUM 3 IDE Clinical Study Protocol</brief_title>
	<detailed_description>The HM3 LVAS intend provide hemodynamic support patient advance , refractory leave ventricular heart failure ; either short term support , bridge cardiac transplantation ( BTT ) myocardial recovery , long term support , destination therapy ( DT ) . The HM3 intend use inside outside hospital .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Subject legal representative sign Informed Consent Form ( ICF ) 2 . Age ≥ 18 year 3 . BSA ≥ 1.2 m2 4 . NYHA Class III dyspnea upon mild physical activity , NYHA Class IV 5 . LVEF ≤ 25 % 6. ) Inotrope dependent OR b ) CI &lt; 2.2 L/min/m2 , inotropes subject must also meet one follow : On Optimal Medical Management ( OMM ) , base current heart failure practice guideline least 45 last 60 day fail respond Advanced Heart Failure least 14 day AND dependent intraaortic balloon pump ( IABP ) least 7 day 7 . Females child bear age must agree use adequate contraception 1 . Etiology heart failure ( HF ) due associate uncorrected thyroid disease , obstructive cardiomyopathy , pericardial disease , amyloidosis restrictive cardiomyopathy 2 . Technical obstacle pose inordinately high surgical risk , judgment investigator 3 . Existence ongoing mechanical circulatory support ( MCS ) IABP 4 . Positive pregnancy test childbearing potential 5 . Presence mechanical aortic valve either convert bioprosthesis oversewn time LVAD implant 6 . History organ transplant 7 . Platelet count &lt; 100,000 x 103/L ( &lt; 100,000/ml ) 8 . Psychiatric disease/disorder , irreversible cognitive dysfunction psychosocial issue likely impair compliance study protocol LVAS management 9 . History confirm , untreated AAA &gt; 5 cm diameter within 6 month enrollment 10 . Presence active , uncontrolled infection 11 . Intolerance anticoagulant antiplatelet therapy peri/postoperative therapy investigator require base upon patient ' health status 12 . Presence one follow risk factor indication severe end organ dysfunction failure : 1 . An INR ≥ 2.0 due anticoagulation therapy 2 . Total bilirubin &gt; 43 umol/L ( 2.5 mg/dl ) , shock liver , biopsy proven liver cirrhosis 3 . History severe chronic obstructive pulmonary disease ( COPD ) define FEV1/FVC &lt; 0.7 , FEV1 &lt; 50 % predict 4 . Fixed pulmonary hypertension recent PVR ≥ 8 Wood unit unresponsive pharmacologic intervention 5 . History stroke within 90 day prior enrollment , history cerebrovascular disease significant ( &gt; 80 % ) uncorrected carotid stenosis 6 . Serum creatinine ≥ 221 umol/L ( 2.5 mg/dl ) need chronic renal replacement therapy 7 . Significant peripheral vascular disease ( PVD ) accompany rest pain extremity ulceration 13 . Patient moderate severe aortic insufficiency without plan correction pump implant 14 . Pre albumin &lt; 150 mg/L ( 15mg/dL ) Albumin &lt; 30g/L ( 3 g/dL ) ( one available ) ; pre albumin &lt; 150 mg/L ( 15mg/dL ) Albumin &lt; 30g/L ( 3 g/dL ) ( available ) 15 . Planned BiVAD support prior enrollment 16 . Patient known hypo hyper coagulable state disseminate intravascular coagulation heparin induce thrombocytopenia 17 . Participation clinical investigation likely confound study result affect study 18 . Any condition HF could limit survival less 24 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Left Ventricular Assist Device</keyword>
	<keyword>Ventricular Dysfunction</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Heart-assist device</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>